Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
INVO Fertility ( (IVF) ) has shared an update.
On February 18, 2026, INVO Fertility closed its acquisition of Indiana-based Family Beginnings P.C. for roughly $760,000, paid in a mix of cash and 400 shares of newly issued Series D non-voting convertible preferred stock. The deal, announced by press release on February 19, 2026, transferred the clinic’s non-clinical assets and was completed under a definitive purchase agreement first unveiled on December 17, 2025.
As part of the transaction, INVO created and filed a Series D Certificate of Designation in Nevada authorizing 4,000 shares of Series D Preferred with a $1,000 stated value each, convertible into common stock at an initial price of $1.20 per share, subject to anti-dilution adjustments and ownership caps. The preferred stock carries no voting rights, ranks senior to common equity, is entitled to as-converted dividends, and may be redeemed by the company, providing structured, non-voting consideration to the seller while limiting immediate equity dilution.
Family Beginnings, a long-established fertility clinic serving Indiana and the broader Midwest, offers a full suite of reproductive services, including IVF, ovulation induction, intrauterine insemination, fertility preservation and diagnostic testing, and was an early adopter of INVO’s INVOcell-enabled intravaginal culture procedure. For the nine months ended September 30, 2025, the clinic generated about $1 million in revenue and $0.2 million in net income, representing roughly 18% of INVO’s clinic revenue for the same period.
The existing medical leadership and staff, led by REI specialist and lab director James Donahue, M.D., who was recognized as a 2026 Castle Connolly Top Doctor, will remain in place under a multi-year agreement to ensure continuity of care. INVO expects to leverage its broader clinical resources, operational infrastructure, and technology investments to grow the clinic beyond its current operating levels while preserving its patient-first, high-touch care model.
Management framed the Family Beginnings acquisition as a meaningful milestone in INVO’s strategy to expand its fertility clinic network and broaden patient access to advanced reproductive care. The transaction underscores the company’s focus on combining organic growth with targeted acquisitions and follows a period that INVO describes as its strongest fundamental position in several years, with the deal enhancing both its geographic footprint and revenue base in the fertility services market.
The most recent analyst rating on (IVF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. is a U.S.-based healthcare services fertility company focused on expanding access to assisted reproductive technology through building, acquiring, and operating fertility clinics and INVO Centers. Its core offerings include traditional IVF services and the proprietary INVOcell device, which enables intravaginal culture procedures positioned as a lower-cost, patient-centric alternative to conventional IVF.
The company operates four fertility clinics in the U.S. and also sells and distributes INVOcell to third-party clinics, targeting patients seeking more affordable, intimate, and effective fertility treatments. INVO’s strategy centers on organic growth and targeted clinic acquisitions to broaden its network and strengthen its market position in advanced reproductive care.
Average Trading Volume: 7,302,265
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.96M
For a thorough assessment of IVF stock, go to TipRanks’ Stock Analysis page.